EFPIA - NEWSLETTER

EFPIA Newsletter 04 December 2025

A defining moment for European life sciences

Europe’s next chapter will be written by the choices we make today. And policy will be the driving force behind whether we succeed in correctly supporting our life sciences sector.

After more than three decades in the pharmaceutical industry, I know one thing: science transforms lives, but policy determines whether innovation thrives or stalls. That reality shapes outcomes for patients and for Europe’s competitiveness. Today, Europeans stand at a defining moment. The choices we make now will determine whether Europe remains a global leader in life sciences or we watch that leadership slip away.

News

02 December 2025 EFPIA response to the Council General Approach on the Critical Medicines Act

EFPIA welcomes today’s adoption of the Council’s General Approach on the Critical Medicines Act (CMA).

Blogs

04 December 2025 Harmonizing health: Impact of international regulatory organisations on pharmaceutical regulatory...

Global alignment is essential for timely access to innovation. This piece explores how ICH and other international organisations...

02 December 2025 Slovenia can become a European leader in Cancer Care: Insights from Dr. Thomas Hofmarcher (Guest...

At the 2025 Tribuna of Hope, one of Slovenia’s most prominent annual gatherings of patient associations, oncology experts,...

Europe has a choice to make

Clinical trials matter. They give patients the earliest access to new medicines, up to 5-10 years before launch and deliver €1-1.5bn to health systems every year. Yet in just five years, Europe has lost 60,000 clinical trial places. Europe is at a crossroads: bring clinical trials back or let the gap grow.

Learn more here.

Events

09 DEC 2025

Impact on TB: Partnerships joining forces to combat TB Online

How the partnerships embodied by IMI2 and EDCTP-2 led to the development of a novel modality for treating TB.

Learn more →

10 DEC 2025

Regulatory impact: what it is and how to achieve it with your IHI project Online

Join the IHI event on 10 December and seize the opportunity to hear from the EMA experts about the best ways for IHI...

Learn more →

The Vaccines Europe pipeline review 2025 is now published

With 91 vaccines and monoclonal antibodies currently in development by our member companies, the report highlights the pivotal role innovation in immunisation plays in addressing emerging and persistent health threats.

It is vital that Europe prepares for this innovation. With the right policies in place, Europe can continue to lead in addressing its population’s evolving health needs and contribute to global health resilience.

We must prepare for tomorrow, today. Explore the pipeline here.

What we are reading

Belgium joins FAST-EU pilot accelerating multinational clinical trials 02 December 2025 (Euractiv)

BRIDGE project launches to advance regulatory sandboxes for healthcare innovation 02 December 2025 (Bridge)

Trials@Home: Comprehensive recommendations for Decentralised Clinical Trials 01 December 2025 (Trials@Home )

Chinese pharma is on the cusp of going global 23 November 2025 (POLITICO)

About the EFPIA newsletter

The European Federation of Pharmaceutical Industries and Associations (EFPIA) represents the pharmaceutical industry operating in Europe. Through its direct membership of 36 national associations and 39 leading pharmaceutical companies, EFPIA is the voice on the EU scene of 1,900 companies committed to researching, developing and bringing to patients new medicines that will improve health and the quality of life around the world.

Tel: +32 (0)2 626 25 55
Communications@efpia.eu

▶